RedHill Biopharma Ltd.
21 Ha'arba'a Street
Tel Aviv, 6473921, Israel
August 15, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street N.E.
Washington, D.C. 20549
Attention: Chris Edwards
| Re: |
RedHill Biopharma Ltd.
Registration Statement on Form F-3
|
Filed August 9, 2024
File No. 333-281417 (the “Registration Statement”)
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules
and Regulations under the Securities Act of 1933, as amended, RedHill Biopharma Ltd. (the “Company”) hereby respectfully requests
that the effective date of the Company’s Registration Statement be accelerated by the Securities and Exchange Commission to 4:30 p.m., Eastern Time on August 19,
2024, or as soon thereafter as practicable.
The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by
telephone call to the Company’s counsel, Haynes and Boone, LLP, by calling Alla Digilova at (212) 659-4993, and that such effectiveness also be confirmed in writing.
| |
Very truly yours,
|
|
| |
|
|
|
REDHILL BIOPHARMA LTD.
|
|
|
|
|
|
|
By:
|
/s/ Dror Ben-Asher
|
|
|
|
Dror Ben-Asher
|
|
|
|
Chief Executive Officer and Chairman of the
Board of Directors
|
|
|
cc:
|
Rick A. Werner, Esq., Haynes and Boone, LLP
|
|
|
Alla Digilova, Esq., Haynes and Boone, LLP
|